Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.89 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | ABAT | P80404 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21063 | 0.94 | — | — | |
| Iodide SCHEMBL20838270 | 0.92 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Hydrochloric Acid SCHEMBL3830237 | 0.92 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Hydrochloric Acid SCHEMBL3847812 | 0.92 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Bromide SCHEMBL31513710 | 0.92 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Ammonia Solution, Strong SCHEMBL4750128 | 0.92 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| SCHEMBL28097374 | 0.92 | LOXL2 (0.94) | LOXL2MAOBTAAR1HRH3IDO1 | |
| SCHEMBL4415525 | 0.86 | LOXL2 (0.84) | LOXL2MAOBTAAR1HRH3IDO1 | |
| Ethylamine SCHEMBL1568352 | 0.86 | LOXL2 (0.84) | LOXL2MAOBTAAR1HRH3IDO1 | |
| SCHEMBL14829415 | 0.86 | LOXL2 (0.84) | LOXL2MAOBTAAR1HRH3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1525201-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | Pfizer Products Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009588-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | LOXL2 2801/4885MAOB 4374/4885TAAR1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.